Guru Fundamental Report for JNJ

Validea's guru fundamental report indicates Johnson & Johnson (JNJ), a large-cap growth stock in the Biotechnology & Drugs sector, rates highly with an 85% score using the Meb Faber-inspired Shareholder Yield Investor model. This strategy, which prioritizes companies returning cash to shareholders via dividends, buybacks, and debt paydown, signals significant interest in JNJ based on its strong underlying fundamentals and valuation.

Analysis

Johnson & Johnson (JNJ) has been identified as a compelling investment candidate by Validea's quantitative model based on Meb Faber's Shareholder Yield strategy, achieving a score of 85%. This rating, considered a signal of notable interest, positions the large-cap Biotechnology & Drugs stock favorably within this specific framework focused on shareholder returns. JNJ's strength is broad-based, passing the strategy's tests for Net Payout Yield, Quality and Debt, Valuation, and Relative Strength. Critically, while the stock fails the specific 'Shareholder Yield' test, its 'PASS' on the 'Net Payout Yield' criterion indicates a strong performance in returning cash to shareholders through the model's preferred combination of dividends, buybacks, and debt paydown. The high overall score suggests the firm's fundamentals and valuation are strongly aligned with the model's parameters, outweighing the single failed metric.

Key Decisions for Investors

• Investors with a quantitative or factor-based approach should view the 85% score as a positive signal, particularly given JNJ's favorable ratings on quality, valuation, and net payout yield.
• It is crucial to investigate the specific reason for the 'FAIL' on the 'Shareholder Yield' criterion to fully understand the composition of JNJ's capital return program and whether it represents a material weakness.
• This analysis is based on a single guru's strategy and should be used as one input among many, supplementing broader fundamental research rather than serving as a sole basis for an investment decision.